Albemarle Corporation

New York Stock Exchange
Back to all articles
Very Bullish +80

Albemarle (ALB) Tops Q1 Earnings and Revenue Estimates

AI-generated analysis

- 📊 Albemarle reported quarterly earnings of $2.95 per share, significantly beating the consensus estimate of $1.24 and reversing last year's loss of -$0.18.

- 📈 Revenue for the quarter ended March 2026 reached $1.43 billion, surpassing analyst expectations by 7.83% compared to $1.08 billion a year ago.

- ⭐ Over the past four quarters, Albemarle has exceeded consensus EPS estimates three times and topped revenue estimates all four times.

- 📉 The stock has gained approximately 37.7% year-to-date, outperforming the S&P 500's gain of just 6%.

- ⚠️ Management's upcoming commentary on sustainability and future growth will heavily influence immediate stock price movement.

- 🏷️ Current Zacks Rank #3 (Hold) reflects mixed pre-earnings estimate revisions and suggests shares may perform in line with the market soon.

- 👀 Future expectations include a consensus EPS of $2.14 and revenues of $1.47 billion for the coming quarter.

- 🏭 The Chemical - Diversified industry is currently ranked in the bottom 39% of all tracked industries, which may weigh on stock performance.

- 🔮 Industry research indicates that top-ranked sectors outperform bottom-ranked ones by a factor of more than 2 to 1.

- 🧪 Peer company Avient (AVNT) is set to report results on May 7 for the same quarter ended March 2026.

Bullish Signals
  • Albemarle reported Q1 earnings of $2.95 per share, significantly beating the consensus estimate of $1.24 and marking a dramatic turnaround from a loss of $0.18 per share a year ago.
  • The company's revenue reached $1.43 billion for the quarter ended March 2026, surpassing analyst estimates by 7.83% and growing 31.5% compared to the prior year.
  • Albemarle has topped consensus revenue estimates four consecutive times over the last four quarters, demonstrating consistent outperformance against market expectations.
  • Shares of Albemarle have appreciated approximately 37.7% since the beginning of the year, vastly outpacing the S&P 500's gain of only 6%.
  • Management has raised forward-looking consensus guidance, with analysts expecting $8.72 EPS and $5.8 billion in revenue for the current fiscal year.
Risk Factors
  • The stock has been assigned a Zacks Rank #3 (Hold), indicating that shares are expected to perform merely in line with the broader market rather than outperforming.
  • Albemarle operates within the Chemical - Diversified industry, which currently ranks in the bottom 39% of over 250 Zacks industries, suggesting a potential for underperformance relative to better-ranked sectors.
  • Although recent earnings beat expectations, the outlook depends heavily on management commentary, as indicated by the article stating there are 'no easy answers' regarding the stock's future price movement beyond immediate numbers.
  • The company's sustainability of positive price movement remains uncertain, with the text explicitly questioning 'what's next for the stock' after such a strong year.
Full Analysis
Albemarle Corporation reported first-quarter earnings that significantly exceeded analyst expectations, delivering $2.95 per share compared to the consensus estimate of $1.24. This represents a massive 138.79% positive surprise and marks a dramatic turnaround from the loss of $0.18 per share recorded in the same period last year. Revenues for the quarter ended March 2026 reached $1.43 billion, which was 7.83% higher than expected by analysts, representing a year-over-year increase from $1.08 billion. The company has now topped earnings estimates three times over its previous four quarters. Despite the strong quarterly performance, the Zacks Rank for Albemarle remains #3 (Hold) ahead of future earnings releases, driven by mixed trends in recent estimate revisions. The stock has outperformed the broader market significantly this year, rising approximately 37.7% compared to the S&P 500's 6% gain. Investors are now looking toward the company's commentary on upcoming earnings calls and industry outlooks, as the Chemical - Diversified industry currently ranks in the bottom 39% of industries tracked by Zacks. For the coming quarter, the current consensus EPS estimate is set at $2.14 on revenue expectations of $1.47 billion. Over the full fiscal year, analysts anticipate earnings of $8.72 per share with total revenues projected to reach $5.8 billion. While Avient Corporation (AVNT) in the same industry has yet to report its own quarter, it is expected to release results on May 7 with consensus estimates adjusted slightly downward based on recent revisions. The sustainability of Albemarle's recent price appreciation will largely depend on whether management guidance and future earnings estimate trends continue to support a positive outlook.